What sector does Phibro Animal Health belong to?

Phibro Animal Health operates in the Health Care sector, specifically the Pharmaceuticals industry, and is listed on the US markets.

What is the current share price of PAHC?

As of the latest available quote, PAHC traded at $35.62. This price is delayed and cached for about 15 minutes.

What is the P/E ratio of PAHC?

Phibro Animal Health has a price-to-earnings (P/E) ratio of about 14.66. The P/E ratio compares the share price to earnings per share and is most useful when compared with sector peers and the company's own history.

What is the market capitalisation of PAHC?

The market capitalisation of Phibro Animal Health is approximately $1.46B.

Is Phibro Animal Health profitable?

For its latest reported financial year, Phibro Animal Health recorded a net profit margin of about 6.57%.

Does PAHC pay a dividend?

Phibro Animal Health currently has a dividend yield of about 1.31%.

What is the return on equity (ROE) of PAHC?

Phibro Animal Health has a return on equity (ROE) of about 25.87%. ROE measures how much profit a company generates relative to shareholders' equity.

What is the 52-week high and low of PAHC?

Over the past 52 weeks, PAHC has traded between a low of $28.25 and a high of $60.08.

Phibro Animal Health

PAHC US Health Care Pharmaceuticals

S&P 600

$35.62

-2.62%

Delayed · cached 15 min

Fair value analysis

PAHC

Phibro Animal Health

$35.62

Close used for this calculation

$42.85Fair value

Financial DNA Score

Profitability · Returns · Balance Sheet · Efficiency · Growth

71/100

Profitability11/25

Returns23/25

Balance Sheet21/25

Efficiency16/25

Growth12/25

Strong

Quality radar

Consensus fair value

$42.85

Below FV

▲ +20.3% against the close used

Model range $3.67 – $73.17

The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.

Price target range & 52-week position

Bear$3.67Fair value$42.85Bull$73.17

FairClose

52-week traded range

52W low $28.5252W high $59.58

The 52-week range is measured from the stored price history, not estimated.

Valuation summary

Trading below the consensus fair value

Phibro Animal Health closed at $35.62, 16.9% below the consensus fair value of $42.85 drawn from 8 valuation models.

Financial DNA score 71/100 — Strong. P/E of 14.7x against the 20x sector multiple the P/E model uses.

Quantitative summary only — not investment advice.

All valuation models

DCF Valuation

$3.67

-89.7%

Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10

g=4.4%, r=10%, tg=3%, n=10yr

P/E Fair Value

$48.60

+36.4%

EPS × 20x (sector P/E)

EPS=2.43, Sector P/E=20x

Peter Lynch (PEG)

$10.74

-69.8%

EPS × Growth% (PEG = 1 is fair)

EPS=2.43, g=4.4%

EV/EBITDA

$73.17

+105.4%

(EBITDA × 12.2x − Net Debt) ÷ Shares

EBITDA=245.91M

Dividend Discount (DDM)

$9.00

-74.7%

D1 ÷ (r − g) where D1 = D0×(1+g)

D0=0.48, r=10%, g=4.4%

Book Value (P/B)

$36.13

+1.4%

BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]

BVPS=9.4, ROE=25.9%, g=4.4%, r=10%

Reverse DCF

$35.62

+0.0%

Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV

Implied: 2.9% | Historical: 4.4%

Margin of Safety

$19.60

-45.0%

Avg(DCF, Graham, P/E) × 75% (25% safety buffer)

Avg fair value=26.14, MoS=25%

Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.

Educational data only. Not a recommendation to buy, sell or hold any security.

Fair value analysis

Consensus fair value

Price target range & 52-week position

Valuation summary

All valuation models

Equity Timer